<DOC>
	<DOCNO>NCT00093496</DOCNO>
	<brief_summary>Phase II trial study effectiveness gemcitabine hydrochloride tanespimycin treat patient recurrent advanced ovarian epithelial primary peritoneal cavity cancer . Drugs use chemotherapy , gemcitabine hydrochloride tanespimycin , work different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Tanespimycin Treating Patients With Recurrent Advanced Ovarian Epithelial Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , time progression , survival patient recurrent advance ovarian epithelial primary peritoneal cavity cancer treat gemcitabine hydrochloride 17-N-allylamino-17-demethoxygeldanamycin ( 17-AAG ) ( tanespimycin ) . II . Determine toxicity regimen patient . III . Correlate effect 17-AAG alone chaperone client proteins tumor sample peripheral blood mononuclear cell response , time progression , survival patient . OUTLINE : This multicenter study . Patients stratify accord gemcitabine hydrochloride therapy ( gemcitabine hydrochloride-naive/no prior exposure gemcitabine hydrochloride vs gemcitabine hydrochloride-resistant/prior exposure gemcitabine hydrochloride single agent disease progression treatment ) . Patients receive tanespimycin intravenously ( IV ) 2 hour day 1 8 course 1 day 2 9 subsequent course gemcitabine hydrochloride IV 30 minute day 7 course 1 day 1 8 subsequent course . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3 month disease progression every 6 month 5 year .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Diagnosis ovarian epithelial primary peritoneal cavity cancer Relapsed disease Persistent disease Platinumresistant disease , define evidence disease would expect nonresponsive additional platinumcontaining regimen contraindication platinumbased chemotherapy 1 following : Failure obtain complete response initial platinum therapy Recurrence &lt; 6 month complete platinumcontaining regimen initial recurrent disease Any situation follow treatment additional chemotherapy regimen ( e.g. , nonplatinum contain regimen ) Relative absolute contraindication platinumbased chemotherapy regimen ( e.g. , platinum allergy ) determine investigator Measurable evaluable disease Patients rise CA 125 level , even absence indicator disease , allow provide CA 125 ≥ 2 time upper limit normal ( ULN ) Patients accessible disease must willing undergo tumor biopsies No CNS metastases Performance status ECOG 02 WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin normal Alkaline phosphatase ≤ 2.5 time ULN AST ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Ejection fraction &gt; 40 % ECHO patient prior anthracycline therapy No significant cardiac disease include follow : New York Heart Association class III IV heart disease History myocardial infraction within past year Uncontrolled dysrhythmias requirement antiarrhythmic drug Poorly control angina No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No history QTc ≥ 500 msec No active ischemic heart disease within past 12 month No congenital long QT syndrome No leave bundle branch block No cardiac symptom ≥ grade 2 No history cardiac toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone , bleomycin , carmustine ) Does meet medicare criterion home oxygen No pulse oximetry rest exercise &lt; 88 % No symptomatic pulmonary disease require medication include follow : Dyspnea exertion Paroxysmal nocturnal dyspnea Oxygen requirement Significant pulmonary disease ( e.g. , chronic obstructive/restrictive pulmonary disease ) No pulmonary symptom ≥ grade 2 No history pulmonary toxicity receive anthracyclines ( e.g. , doxorubicin hydrochloride , daunorubicin hydrochloride , mitoxantrone , bleomycin , carmustine ) K+ , Mg ++ , Ca ++ normal No seizure disorder No uncontrolled infection No history serious allergic reaction egg More 4 week since prior immunotherapy More 4 week since prior biologic therapy No concurrent immunotherapy No concurrent routine prophylactic colonystimulating factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) See Disease Characteristics More 4 week since prior chemotherapy ( 6 week mitomycin nitrosoureas ) recover Prior gemcitabine hydrochloride allow provided 1 follow criterion meet : Patients prior exposure gemcitabine hydrochloride Patients prior exposure gemcitabine hydrochloride single agent experience progressive disease treatment No concurrent chemotherapy No prior radiotherapy &gt; 25 % bone marrow No history radiotherapy potentially include heart field ( e.g. , mantle ) Chest wall irradiation radiotherapy technique include heart radiation field area allow More 4 week since prior radiotherapy More 4 week since prior radiopharmaceutical No concurrent radiotherapy No concurrent investigational therapy No concurrent medication may prolong QTc</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>